5 MIN PRESENTATION
Press about us
Try our old website
Artificial intelligence for drug discovery and aging research
We provide services to academia, pharmaceutical and cosmetics companies:
Advanced deep learning solutions
Custom drug discovery engines
Custom biomarkers discovery
New tools for aging research
We license 827 drug-disease predictions and biomarkers:
573 antineoplastic agents
114 metabolic regulators
41 CVD disease candidates
38 CNS agents
37 anti-cancer immune response boosters
Aging biomarkers (biochemical and transcriptional)
Cancer biomarkers (biochemical and transcriptional)
Our mission is to extend healthy longevity
Some of our current projects
Exclusive partnership with Life Extension
About Insilico Medicine
Basel Life Science Week: Practical Applications of Aging Research Forum
Embryonic AI: Analysis of Embryonic State using Deep Neural Networks (Property of Biotime, Inc)
Aging Researcher Insilico Medicine Takes Top Prize at PMWC 2015
Over 150 academic and industry collaborators worldwide
CHECK OUT OUR LATEST NEWS
Partnership of LongeVC and Insilico Medicine to screen for projects maximizing longevity dividend
At the "Ageing Societies 2016," The Economist conference in London, LongeVC and Insilico Medicine entered into a research collaboration.
BGRF scientists publish seminal paper and announce project to develop biomarkers of aging
Biogerontology Research Foundation scientists announce collaboration to develop biomarkers of aging with Johns Hopkins University, Albert Einstein College of Medicine, Boston University, Novartis, Nestle & Biotime Inc.
In silico Pathway Activation Network Decomposition Analysis (iPANDA)
A novel approach for precision medicine and drug discovery on gene expression data.
Aging.AI 2.0 is available for testing
Comparing Aging.AI 1.0 using 41 blood biochemistry biomarkers, Aging.AI 2.0 uses just 33 parameters from the blood test and has slightly higher mean absolute error.
Insilico Medicine and Life Extension collaborating on geroprotector development
Advances in computational biology and artificial intelligence used to identify compounds with potential to extend human life.
First M&A in aging bioinformatics
Insilico Medicine and InSilicoScreen merge to take human aging research to the next level.
Insilico Medicine wins ACS Editors' Choice Award
Our recent paper published in
received the American Chemical Society Editors' Choice Award.
Artificial Neural Networks guess patient's age with surprising accuracy
Deep biomarkers of human aging based on a simple blood test.
Insilico Medicine presents deep learned biomarkers
Insilico Medicine to present a range of deep learned biomarkers of ageing and deep learned predictors of biological age at the RE-WORK Deep learning in Healthcare Summit.
The first AI system for human embryonic state analysis is available for testing
BioTime and Insilico Medicine collaborate on embryonic artificial intelligence using deep learning to study embryonic development.
Pharma.AI launches to apply artificial intelligence to drug discovery and development
This tactic allows marketers to publish targeted ads in front of an interest category or a defined audience.
Insilico Medicine and Biotime to develop Embryonic.AI
Insilico Medicine and ChemDiv to develop and market targeted panels of oncology compounds
Insilico Medicine and Life Extension form a partnership to develop aging biomarkers and geroprotectors
Insilico Medicine and Nazarbayev University start a collaboration to develop population-level biomarkers of aging
OUR LATEST PUBLICATION
Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development
Nature Communications, 16 November 2016
"A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation." Oncotarget (2015).
"Signaling pathways activation profiles make better markers of cancer than expression of individual genes." Oncotarget (2014).
"Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data." Molecular pharmaceutics (2016).
"Applications of deep learning in biomedicine."
"Deep biomarkers of human aging: Application of deep neural networks to biomarker development."
"In search for geroprotectors: in silico screening and
validation of signalome-level mimetics of young healthy state."
Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development."
Alex Zhavoronkov, PhD
Qingsong Zhu, PhD
Gene Makarev, PhD
Ivan Ozerov, PhD
Quentin Vanhaelen, PhD
We have 39 scientists hired through hackathons and competitions worldwide in the US, Poland, Belgium, and Russia.
30% of our staff are women.
Scientific advisory board
Charles Cantor, PhD
ex-Director of the Human Genome Project and the Center for Advanced Biotechnology at Boston University
Michael Levitt, PhD
2013 Nobel Laureate (Chemistry) Professor, Stanford University
Bud Mishra, PhD
Professor of computer science at Courant Institute, professor of biology at Mt. Sinai School of Medicine and NYU School of Medicine
Donald Small, MD, PhD
Director of pediatric oncology at the Johns Hopkins Kimmel Cancer Center
Yuri Nikolsky, PhD
ex-VP, Thomson Reuters
Director, Skolkovo Found
Kristen Fortney, PhD
Postdoctoral fellow of Ellison Medical Foundation/American Federation for Aging Research at Stanford University
Alexey Moskalev, PhD
Professor at Syktyvkar State University
Head of the laboratory of Molecular radiobiology and gerontology at the Institute of biology of Komi Science Center of Ural division of RAS
4th Annual Life Science R&D
Intelligence Leaders Forum
January 24-26, 2017
Deep Learning in Healthcare Summit
February 23-24, 2017
Deep Learning in Healthcare Summit
May 11-12, 2017
Press about us
Insilico Medicine, Inc.
Emerging Technology Centers
Johns Hopkins University Eastern Campus
Suite B301, 1101 East 33rd St.
Baltimore, MD 21218
Phone: +1 443 451 7212
Fax: +1 443 451 7210
© 2016 All Right Reserved. Insilico Medicine, Inc.